Singular Genomics Systems (NASDAQ:OMIC) Rating Increased to Buy at Zacks Investment Research
Singular Genomics Systems (NASDAQ:OMIC – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Saturday, Zacks.com reports. The firm currently has a $3.75 price objective on the stock. Zacks Investment Research‘s target price suggests a potential upside of 12.28% from the stock’s […]
Michaelj Pellini Revelation Capital Management Goldman Sachs Group Inc Zacks Investment Research Blackrock Inc Singular Genomics Systems Inc
Source: etfdailynews.com